Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Dosregim för psoriasisartrit

Den rekommenderade dosen är 160 mg subkutan injektion (två 80mg injektioner) vecka 0, sedan 80 mg var 4:e vecka.

Dosage Regimen for Psoriatic Arthritis

The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) every 4 weeks thereafter.1

For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis.1

Discontinuation of treatment

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1

Dosing in specific patient populations

In elderly patients (≥ 65 years) is no dose adjustment required. There is limited information in subjects aged ≥ 75 years.1

Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1

Therapeutic Indication

Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.1

Ixekizumab is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Ixekizumab is indicated.1


1. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.


cDMARD = conventional disease-modifying antirheumatic drug

HIV = human immunodeficiency virus

MTX = methotrexate

NSAID = nonsteroidal anti-inflammatory drug

PsA = psoriatic arthritis

Q2W = every 2 weeks

Q4W = every 4 weeks

SC = subcutaneous

TB = tuberculosis

TNF = tumor necrosis factor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M06 05

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss